This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, L. Articles by Gerson, S. L. Search for Related Content PubMed PubMed Citation Articles by Liu, L. Articles by Gerson, S. L.

Base Excision Repair as a Therapeutic Target in Colon Cancer¹

Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106

Base excision repair (BER) is a fundamental cellular process used to reduce the cytotoxicity of alkylating agent chemotherapy. Heretofore, no therapeutic agents have targeted this DNA repair pathway. Methoxyamine (MX), which binds abasic sites, acting as an inhibitor of BER, was evaluated in combination with the methylating agent temozolomide (TMZ). Three human colon cancer cell lines were used, SW480 cells, which are wild-type for mismatch repair genes and have mutated p53, HCT116 cells, which are mutant in hMLH1 and wild-type for p53, and HCT15 cells, which are mutant in hMSH6 and mutant in p53 as well. Nude mice carrying these tumors received TMZ alone or in combination with MX or O⁶-benzylguanine (BG), an inhibitor of O⁶-alkylguanine DNA-alkyltransferase, daily i.p. for 5 consecutive days. At the highest tolerable dose of TMZ (120 mg/kg), a tumor growth delay of approximately 9.3 ± 1.2 days was noted in SW480. Addition of BG resulted in a tumor growth delay of 25 ± 2.4 days accompanied by significant weight loss (23%) and severe myelosuppression. In contrast, SW480 tumor-bearing mice treated with MX + TMZ had cessation of tumor growth for 50 ± 13 days and very slow regrowth, yielding tumor growth delays of >70 ± 14 days (P < 0.002) without additive systemic toxicity. HCT116 and HCT15 xenografts were completely resistant to treatment with TMZ alone or in combination with BG. However, treatment with MX + TMZ induced significant tumor growth delays (20 ± 1.4 days in HCT116 and 14 ± 3.1 days in HCT15 xenografts, P < 0.05). These studies demonstrate that a significant enhancement of the antitumor effect of TMZ by MX was observed in human colon cancer xenografts with mismatch repair proficiency and deficiency. DNA BER may be a useful pharmacological target through which tumor cells can be sensitized to alkylating therapeutic agents.

This article has been cited by other articles:

				L. Yan, A. Bulgar, Y. Miao, V. Mahajan, J. R. Donze, S. L. Gerson, and L. Liu Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase II{alpha} Clin. Cancer Res., March 1, 2007; 13(5): 1532 - 1539. [Abstract] [Full Text] [PDF]

				G.-M. Zou, M.-H. Luo, A. Reed, M. R. Kelley, and M. C. Yoder Ape1 regulates hematopoietic differentiation of embryonic stem cells through its redox functional domain Blood, March 1, 2007; 109(5): 1917 - 1922. [Abstract] [Full Text] [PDF]

				M. L. Fishel, Y. He, M. L. Smith, and M. R. Kelley Manipulation of Base Excision Repair to Sensitize Ovarian Cancer Cells to Alkylating Agent Temozolomide Clin. Cancer Res., January 1, 2007; 13(1): 260 - 267. [Abstract] [Full Text] [PDF]

				J. R. Hart, O. Glebov, R. J. Ernst, I. R. Kirsch, and J. K. Barton DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators PNAS, October 17, 2006; 103(42): 15359 - 15363. [Abstract] [Full Text] [PDF]

				T. Yan, Y. Seo, J. E. Schupp, X. Zeng, A. B. Desai, and T. J. Kinsella Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol. Cancer Ther., April 1, 2006; 5(4): 893 - 902. [Abstract] [Full Text] [PDF]

				L. Liu and S. L. Gerson Targeted Modulation of MGMT: Clinical Implications Clin. Cancer Res., January 15, 2006; 12(2): 328 - 331. [Abstract] [Full Text] [PDF]

				S. Narayan, A. S. Jaiswal, and R. Balusu Tumor Suppressor APC Blocks DNA Polymerase {beta}-dependent Strand Displacement Synthesis during Long Patch but Not Short Patch Base Excision Repair and Increases Sensitivity to Methylmethane Sulfonate J. Biol. Chem., February 25, 2005; 280(8): 6942 - 6949. [Abstract] [Full Text] [PDF]

				M. Rinne, D. Caldwell, and M. R. Kelley Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells Mol. Cancer Ther., August 1, 2004; 3(8): 955 - 967. [Abstract] [Full Text] [PDF]

				L. Liu, L. Yan, J. R. Donze, and S. L. Gerson Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts Mol. Cancer Ther., October 1, 2003; 2(10): 1061 - 1066. [Abstract] [Full Text] [PDF]

				P. Taverna, H.-s. Hwang, J. E. Schupp, T. Radivoyevitch, N. N. Session, G. Reddy, D. A. Zarling, and T. J. Kinsella Inhibition of Base Excision Repair Potentiates Iododeoxyuridine-induced Cytotoxicity and Radiosensitization Cancer Res., February 15, 2003; 63(4): 838 - 846. [Abstract] [Full Text] [PDF]